Bio & Pharma
Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey
The South Korean biopharmaceutical company's autoimmune disease medicine Remsima controls 51% of the market
By Apr 21, 2023 (Gmt+09:00)
1
Min read
Most Read
Hankook Tire buys $1 bn Hanon Systems stake from Hahn & Co.
NPS to hike risky asset purchases under simplified allocation system
Osstem to buy Brazil’s No. 3 dental implant maker Implacil
S.Korea's LS Materials set to boost earnings ahead of IPO process
UAE to invest up to $1 bn in S.Korean ventures
South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turkish market for hospital prescriptions.
Starting with its autoimmune disease treatment Remsima (active ingredient infliximab) in 2017, the company set up a direct sales distribution network through its locally incorporated business Celltrion Healthcare Turkiye. Last year, Remsima controlled 51% of the country's market.
The company added that its anti-cancer antibody biosimilar Herzuma (trastuzumab) last year held a commanding 71% of the market and leukemia cancer treatment Truxima (rituximab) 76%.
Beginning with Remsima SC next year, Celltrion Healthcare will use its direct sales experience to launch new products in Turkey every year like the rheumatoid arthritis medicine Yuflyma and anti-cancer drug Vegzelma.
"We will do our best to continue growth next year, when we release follow-up products on the Turkiye market, a bridgehead linking Europe, the Middle East and Asia," Celltrion Healthcare Turkiye General Manager Kang Seok-hoon said.
Write to Jeong Min Nam at peux@hankyung.com
More to Read
-
Bio & PharmaS.Korea's Celltrion Healthcare launches Vegzelma in US
Apr 17, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaCelltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan
Jan 26, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaCelltrion Healthcare lands biosimilar deal in Brazil for 2nd straight year
Jan 11, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaCelltrion Healthcare logs record-high Q2 revenue on back of Remsima
Aug 17, 2022 (Gmt+09:00)
2 Min read
Comment 0
LOG IN